Barclays PLC Cue Biopharma, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 6,029 shares of CUE stock, worth $9,405. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,029

Previous 6,029 -0.0%

Holding current value

$9,405

Previous $5,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$0.45 - $1.08 $5,521 - $13,250	-12,269 Reduced 67.05%	6,029 $5,000
Q2 2024 Aug 14, 2024	SELL	$1.24 - $2.18 $16,251 - $28,571	-13,106 Reduced 41.73%	18,298 $22,000
Q1 2024 May 15, 2024	SELL	$1.77 - $3.09 $42,701 - $74,546	-24,125 Reduced 43.45%	31,404 $59,000
Q4 2023 Feb 15, 2024	BUY	$1.72 - $3.1 $74,847 - $134,899	43,516 Added 362.24%	55,529 $146,000
Q3 2023 Nov 07, 2023	SELL	$2.23 - $4.69 $2,080 - $4,375	-933 Reduced 7.21%	12,013 $28,000
Q2 2023 Aug 03, 2023	BUY	$3.11 - $4.91 $21,511 - $33,962	6,917 Added 114.73%	12,946 $48,000
Q4 2022 Feb 13, 2023	SELL	$2.39 - $3.95 $380 - $628	-159 Reduced 2.57%	6,029 $17,000
Q3 2022 Nov 03, 2022	SELL	$2.23 - $3.37 $2,287 - $3,457	-1,026 Reduced 14.22%	6,188 $14,000
Q2 2022 Aug 12, 2022	SELL	$2.49 - $5.92 $12,442 - $29,582	-4,997 Reduced 40.92%	7,214 $18,000
Q1 2022 May 16, 2022	SELL	$4.41 - $12.28 $142,046 - $395,538	-32,210 Reduced 72.51%	12,211 $60,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $267,546 - $439,752	24,636 Added 124.52%	44,421 $503,000
Q3 2021 Nov 09, 2021	BUY	$10.06 - $15.3 $142,379 - $216,540	14,153 Added 251.3%	19,785 $288,000
Q2 2021 Aug 13, 2021	SELL	$10.9 - $14.53 $208,168 - $277,493	-19,098 Reduced 77.23%	5,632 $66,000
Q1 2021 May 13, 2021	BUY	$11.2 - $16.09 $127,545 - $183,232	11,388 Added 85.35%	24,730 $302,000
Q4 2020 Feb 11, 2021	SELL	$11.12 - $16.4 $63,228 - $93,250	-5,686 Reduced 29.88%	13,342 $166,000
Q3 2020 Nov 12, 2020	BUY	$15.05 - $23.54 $52,389 - $81,942	3,481 Added 22.39%	19,028 $286,000
Q2 2020 Aug 12, 2020	BUY	$12.7 - $30.73 $112,712 - $272,728	8,875 Added 133.02%	15,547 $381,000
Q1 2020 May 13, 2020	SELL	$9.85 - $22.27 $130,857 - $295,856	-13,285 Reduced 66.57%	6,672 $94,000
Q4 2019 Feb 10, 2020	BUY	$7.06 - $17.47 $40,397 - $99,963	5,722 Added 40.2%	19,957 $317,000
Q3 2019 Nov 14, 2019	BUY	$6.78 - $9.28 $17,648 - $24,155	2,603 Added 22.38%	14,235 $120,000
Q2 2019 Aug 14, 2019	BUY	$7.18 - $9.65 $46,641 - $62,686	6,496 Added 126.48%	11,632 $105,000
Q1 2019 May 15, 2019	BUY	$4.7 - $9.29 $24,139 - $47,713	5,136 New	5,136 $40,000
Q4 2018 Feb 14, 2019	SELL	$4.35 - $8.73 $28,831 - $57,862	-6,628 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$7.91 - $11.89 $42,191 - $63,421	5,334 Added 412.21%	6,628 $60,000
Q2 2018 Aug 14, 2018	SELL	$10.93 - $14.48 $6,000 - $7,949	-549 Reduced 29.79%	1,294 $15,000
Q1 2018 May 15, 2018	BUY	$11.63 - $17.25 $21,434 - $31,791	1,843 New	1,843 $26,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $55.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account